PARP inhibitors have been extensively studied in combination with chemotherapeutic drugs in cancers such as ovarian cancer, breast cancer, small cell lung carcinoma (SCLC), prostate, and pancreatic cancer [138,139,140,141]. The gene discussed is PARP1; the disease is small cell lung carcinoma.